ROBBIN is Agenus' planned randomized global Phase 3 trial evaluating neoadjuvant BOT+BAL followed by standard of care versus standard of care alone in previously untreated high-risk Stage II and Stage IIIMSS colon cancer.
Show Caption. Hide Caption. Subscribe to the Clarion Ledger. If you are not a subscriber, consider subscribing now. You will also get access to the Clarion Ledger's E-Edition, the electronic replica of the print publication along with print archives.
MONTEREY PARK, CA / ACCESSNewswire / July 3, 2026 / Maison Solutions Inc. (Nasdaq.MSS) ("Maison Solutions" or the "Company"), a specialty grocery retailer offering traditional Asian food and merchandise to U.S ... About Maison Solutions Inc ... Email. ... ....
). MSSSeriesTrust. One Rock Fund. Ticker. ONERX. Supplement dated June 26, 2026 to the Prospectus, Summary Prospectus, and ... MSS Series Trust published this content on June 26, 2026, and is solely responsible for the information contained herein ... (noodl.
AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study of botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 ...